Details
Stereochemistry | ACHIRAL |
Molecular Formula | C26H32N4O4S |
Molecular Weight | 496.622 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)N(CCCCOCC(=O)NS(C)(=O)=O)C1=NC(C2=CC=CC=C2)=C(N=C1)C3=CC=CC=C3
InChI
InChIKey=QXWZQTURMXZVHJ-UHFFFAOYSA-N
InChI=1S/C26H32N4O4S/c1-20(2)30(16-10-11-17-34-19-24(31)29-35(3,32)33)23-18-27-25(21-12-6-4-7-13-21)26(28-23)22-14-8-5-9-15-22/h4-9,12-15,18,20H,10-11,16-17,19H2,1-3H3,(H,29,31)
Molecular Formula | C26H32N4O4S |
Molecular Weight | 496.622 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionCurator's Comment: Description was created based on several sources, including
https://www.drugbank.ca/drugs/DB11362
Curator's Comment: Description was created based on several sources, including
https://www.drugbank.ca/drugs/DB11362
Selexipag was approved by the United States FDA on December 22, 2015 for the treatment of pulmonary arterial hypertension (PAH) to delay disease progression and reduce risk of hospitalization. PAH is a relatively rare disease with usually a poor prognosis requiring more treatment options to prolong long-term outcomes. Marketed by Actelion Pharmaceuticals under brand name Uptravi, selexipag and its active metabolite, ACT-333679 (MRE-269), act as agonists of the prostacyclin receptor to increase vasodilation in the pulmonary circulation and decrease elevated pressure in the blood vessels supplying blood to the lungs. Selexipag is a selective prostacyclin (IP, also called PGI2) receptor agonist. The key features of pulmonary arterial hypertension include a decrease in prostacyclin and prostacyclin synthase (enzyme that helps produce prostacyclin) in the lung. Prostacyclin is a potent vasodilator with anti-proliferative, anti-inflammatory, and anti-thrombotic effects; therefore, there is strong rationale for treatment with IP receptor agonists. Selexipag is chemically distinct as it is not PGI2 or a PGI2 analogue and has high selectivity for the IP receptor. It is metabolized by carboxylesterase 1 to yield an active metabolite (ACT-333679) that is approximately 37 times more potent than selexipag. Both selexipag and its metabolite are selective for the IP receptor over other prostanoid receptors. Selexipag is marketed under the brand name UPTRAVI, indicated for the
treatment of pulmonary arterial hypertension (PAH, WHO Group I) to delay disease progression and reduce the risk of hospitalization for PAH.
CNS Activity
Sources: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/003774/WC500207175.pdf
Curator's Comment: Selexipag hardly passes the blood-brain-barrier
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: GO:0070527 |
5.5 µM [IC50] | ||
Target ID: CHEMBL1995 |
4.0 nM [EC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | UPTRAVI Approved UseUPTRAVI is a prostacyclin receptor agonist indicated for the
treatment of pulmonary arterial hypertension (PAH, WHO Group I)
to delay disease progression and reduce the risk of hospitalization for
PAH. Launch Date2015 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
2.2 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25850750 |
100 μg single, oral dose: 100 μg route of administration: Oral experiment type: SINGLE co-administered: |
SELEXIPAG plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
3.4 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25850750 |
200 μg single, oral dose: 200 μg route of administration: Oral experiment type: SINGLE co-administered: |
SELEXIPAG plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
5.98 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25850750 |
400 μg single, oral dose: 400 μg route of administration: Oral experiment type: SINGLE co-administered: |
SELEXIPAG plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
11.19 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25850750 |
600 μg single, oral dose: 600 μg route of administration: Oral experiment type: SINGLE co-administered: |
SELEXIPAG plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
11.53 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25850750 |
800 μg single, oral dose: 800 μg route of administration: Oral experiment type: SINGLE co-administered: |
SELEXIPAG plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
1.85 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25850750 |
200 μg 1 times / day steady-state, oral dose: 200 μg route of administration: Oral experiment type: STEADY-STATE co-administered: |
SELEXIPAG plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
4.12 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25850750 |
400 μg 1 times / day steady-state, oral dose: 400 μg route of administration: Oral experiment type: STEADY-STATE co-administered: |
SELEXIPAG plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
5.29 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25850750 |
600 μg 1 times / day steady-state, oral dose: 600 μg route of administration: Oral experiment type: STEADY-STATE co-administered: |
SELEXIPAG plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
4.61 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25850750 |
100 μg single, oral dose: 100 μg route of administration: Oral experiment type: SINGLE co-administered: |
SELEXIPAG plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
6.77 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25850750 |
200 μg single, oral dose: 200 μg route of administration: Oral experiment type: SINGLE co-administered: |
SELEXIPAG plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
12.35 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25850750 |
400 μg single, oral dose: 400 μg route of administration: Oral experiment type: SINGLE co-administered: |
SELEXIPAG plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
23.27 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25850750 |
600 μg single, oral dose: 600 μg route of administration: Oral experiment type: SINGLE co-administered: |
SELEXIPAG plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
24.97 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25850750 |
800 μg single, oral dose: 800 μg route of administration: Oral experiment type: SINGLE co-administered: |
SELEXIPAG plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
5.38 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25850750 |
200 μg 1 times / day steady-state, oral dose: 200 μg route of administration: Oral experiment type: STEADY-STATE co-administered: |
SELEXIPAG plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
9.7 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25850750 |
400 μg 1 times / day steady-state, oral dose: 400 μg route of administration: Oral experiment type: STEADY-STATE co-administered: |
SELEXIPAG plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
13.78 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25850750 |
600 μg 1 times / day steady-state, oral dose: 600 μg route of administration: Oral experiment type: STEADY-STATE co-administered: |
SELEXIPAG plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
0.7 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25850750 |
100 μg single, oral dose: 100 μg route of administration: Oral experiment type: SINGLE co-administered: |
SELEXIPAG plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
0.8 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25850750 |
200 μg single, oral dose: 200 μg route of administration: Oral experiment type: SINGLE co-administered: |
SELEXIPAG plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
1 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25850750 |
400 μg single, oral dose: 400 μg route of administration: Oral experiment type: SINGLE co-administered: |
SELEXIPAG plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
1.9 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25850750 |
600 μg single, oral dose: 600 μg route of administration: Oral experiment type: SINGLE co-administered: |
SELEXIPAG plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
2.3 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25850750 |
800 μg single, oral dose: 800 μg route of administration: Oral experiment type: SINGLE co-administered: |
SELEXIPAG plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
1.14 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25850750 |
200 μg 1 times / day steady-state, oral dose: 200 μg route of administration: Oral experiment type: STEADY-STATE co-administered: |
SELEXIPAG plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
1.41 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25850750 |
400 μg 1 times / day steady-state, oral dose: 400 μg route of administration: Oral experiment type: STEADY-STATE co-administered: |
SELEXIPAG plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
1.24 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25850750 |
600 μg 1 times / day steady-state, oral dose: 600 μg route of administration: Oral experiment type: STEADY-STATE co-administered: |
SELEXIPAG plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1% |
, oral |
SELEXIPAG plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
900 ug 2 times / day multiple, oral Studied dose Dose: 900 ug, 2 times / day Route: oral Route: multiple Dose: 900 ug, 2 times / day Sources: |
unhealthy, 18 to 75 years Health Status: unhealthy Age Group: 18 to 75 years Sex: M+F Sources: |
Disc. AE: Headache, Diarrhea... AEs leading to discontinuation/dose reduction: Headache Sources: Diarrhea Nausea Myalgia Abdominal pain Pain in extremity Dizziness |
900 ug 2 times / day multiple, oral Studied dose Dose: 900 ug, 2 times / day Route: oral Route: multiple Dose: 900 ug, 2 times / day Sources: |
unhealthy, 19 to 75 years Health Status: unhealthy Age Group: 19 to 75 years Sex: M+F Sources: |
Other AEs: Headache... Other AEs: Headache (65%) Sources: |
900 ug 2 times / day multiple, oral Studied dose Dose: 900 ug, 2 times / day Route: oral Route: multiple Dose: 900 ug, 2 times / day Sources: |
unhealthy, 20 to 75 years Health Status: unhealthy Age Group: 20 to 75 years Sex: M+F Sources: |
Other AEs: Diarrhoea... Other AEs: Diarrhoea (42%) Sources: |
900 ug 2 times / day multiple, oral Studied dose Dose: 900 ug, 2 times / day Route: oral Route: multiple Dose: 900 ug, 2 times / day Sources: |
unhealthy, 21 to 75 years Health Status: unhealthy Age Group: 21 to 75 years Sex: M+F Sources: |
Other AEs: Pain in jaw... Other AEs: Pain in jaw (26%) Sources: |
900 ug 2 times / day multiple, oral Studied dose Dose: 900 ug, 2 times / day Route: oral Route: multiple Dose: 900 ug, 2 times / day Sources: |
unhealthy, 22 to 75 years Health Status: unhealthy Age Group: 22 to 75 years Sex: M+F Sources: |
Other AEs: Nausea... Other AEs: Nausea (33%) Sources: |
900 ug 2 times / day multiple, oral Studied dose Dose: 900 ug, 2 times / day Route: oral Route: multiple Dose: 900 ug, 2 times / day Sources: |
unhealthy, 23 to 75 years Health Status: unhealthy Age Group: 23 to 75 years Sex: M+F Sources: |
Other AEs: Myalgia... Other AEs: Myalgia (16%) Sources: |
900 ug 2 times / day multiple, oral Studied dose Dose: 900 ug, 2 times / day Route: oral Route: multiple Dose: 900 ug, 2 times / day Sources: |
unhealthy, 24 to 75 years Health Status: unhealthy Age Group: 24 to 75 years Sex: M+F Sources: |
Other AEs: Vomiting... Other AEs: Vomiting (18%) Sources: |
900 ug 2 times / day multiple, oral Studied dose Dose: 900 ug, 2 times / day Route: oral Route: multiple Dose: 900 ug, 2 times / day Sources: |
unhealthy, 25 to 75 years Health Status: unhealthy Age Group: 25 to 75 years Sex: M+F Sources: |
Other AEs: Pain in extremity... Other AEs: Pain in extremity (17%) Sources: |
900 ug 2 times / day multiple, oral Studied dose Dose: 900 ug, 2 times / day Route: oral Route: multiple Dose: 900 ug, 2 times / day Sources: |
unhealthy, 26 to 75 years Health Status: unhealthy Age Group: 26 to 75 years Sex: M+F Sources: |
Other AEs: Flushing... Other AEs: Flushing (12%) Sources: |
900 ug 2 times / day multiple, oral Studied dose Dose: 900 ug, 2 times / day Route: oral Route: multiple Dose: 900 ug, 2 times / day Sources: |
unhealthy, 27 to 75 years Health Status: unhealthy Age Group: 27 to 75 years Sex: M+F Sources: |
Other AEs: Arthralgia... Other AEs: Arthralgia (11%) Sources: |
900 ug 2 times / day multiple, oral Studied dose Dose: 900 ug, 2 times / day Route: oral Route: multiple Dose: 900 ug, 2 times / day Sources: |
unhealthy, 28 to 75 years Health Status: unhealthy Age Group: 28 to 75 years Sex: M+F Sources: |
Other AEs: Anaemia... Other AEs: Anaemia (8%) Sources: |
900 ug 2 times / day multiple, oral Studied dose Dose: 900 ug, 2 times / day Route: oral Route: multiple Dose: 900 ug, 2 times / day Sources: |
unhealthy, 29 to 75 years Health Status: unhealthy Age Group: 29 to 75 years Sex: M+F Sources: |
Other AEs: Abdominal pain... Other AEs: Abdominal pain (8%) Sources: |
900 ug 2 times / day multiple, oral Studied dose Dose: 900 ug, 2 times / day Route: oral Route: multiple Dose: 900 ug, 2 times / day Sources: |
unhealthy, 30 to 75 years Health Status: unhealthy Age Group: 30 to 75 years Sex: M+F Sources: |
Other AEs: Decreased appetite... Other AEs: Decreased appetite (6%) Sources: |
900 ug 2 times / day multiple, oral Studied dose Dose: 900 ug, 2 times / day Route: oral Route: multiple Dose: 900 ug, 2 times / day Sources: |
unhealthy, 31 to 75 years Health Status: unhealthy Age Group: 31 to 75 years Sex: M+F Sources: |
Other AEs: Pain... Other AEs: Pain (3%) Sources: |
900 ug 2 times / day multiple, oral Studied dose Dose: 900 ug, 2 times / day Route: oral Route: multiple Dose: 900 ug, 2 times / day Sources: |
unhealthy, 32 to 75 years Health Status: unhealthy Age Group: 32 to 75 years Sex: M+F Sources: |
Other AEs: Nasopharyngitis... Other AEs: Nasopharyngitis (13%) Sources: |
1800 ug 2 times / day multiple, oral Highest studied dose Dose: 1800 ug, 2 times / day Route: oral Route: multiple Dose: 1800 ug, 2 times / day Sources: |
healthy, mean age of 36.4 years Health Status: healthy Age Group: mean age of 36.4 years Sex: M Sources: |
Disc. AE: Nausea, Nightmares... AEs leading to discontinuation/dose reduction: Nausea (12.5%) Sources: Nightmares (12.5%) |
1600 ug 2 times / day multiple, oral MTD Dose: 1600 ug, 2 times / day Route: oral Route: multiple Dose: 1600 ug, 2 times / day Sources: |
healthy, mean age of 36.4 years Health Status: healthy Age Group: mean age of 36.4 years Sex: M Sources: |
|
1000 ug 2 times / day multiple, oral Studied dose Dose: 1000 ug, 2 times / day Route: oral Route: multiple Dose: 1000 ug, 2 times / day Sources: |
healthy, mean age of 36.4 years Health Status: healthy Age Group: mean age of 36.4 years Sex: M Sources: |
Disc. AE: Headache... AEs leading to discontinuation/dose reduction: Headache (11.1%) Sources: |
400 ug 2 times / day multiple, oral Studied dose Dose: 400 ug, 2 times / day Route: oral Route: multiple Dose: 400 ug, 2 times / day Sources: |
healthy, mean age of 36.4 years Health Status: healthy Age Group: mean age of 36.4 years Sex: M Sources: |
Disc. AE: Myalgia... AEs leading to discontinuation/dose reduction: Myalgia (8.3%) Sources: |
600 ug 2 times / day multiple, oral Studied dose Dose: 600 ug, 2 times / day Route: oral Route: multiple Dose: 600 ug, 2 times / day Sources: |
healthy, mean age of 36.4 years Health Status: healthy Age Group: mean age of 36.4 years Sex: M Sources: |
Disc. AE: Feeling hot, Myalgia... AEs leading to discontinuation/dose reduction: Feeling hot (9.1%) Sources: Myalgia (9.1%) Disturbance in attention (9.1%) Dysaesthesia (9.1%) Palpitations (9.1%) Tinnitus (9.1%) Dizziness (9.1%) Dry mouth (9.1%) |
3200 ug 1 times / day single, oral Studied dose Dose: 3200 ug, 1 times / day Route: oral Route: single Dose: 3200 ug, 1 times / day Sources: |
unhealthy |
Other AEs: Nausea... |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Abdominal pain | Disc. AE | 900 ug 2 times / day multiple, oral Studied dose Dose: 900 ug, 2 times / day Route: oral Route: multiple Dose: 900 ug, 2 times / day Sources: |
unhealthy, 18 to 75 years Health Status: unhealthy Age Group: 18 to 75 years Sex: M+F Sources: |
Diarrhea | Disc. AE | 900 ug 2 times / day multiple, oral Studied dose Dose: 900 ug, 2 times / day Route: oral Route: multiple Dose: 900 ug, 2 times / day Sources: |
unhealthy, 18 to 75 years Health Status: unhealthy Age Group: 18 to 75 years Sex: M+F Sources: |
Dizziness | Disc. AE | 900 ug 2 times / day multiple, oral Studied dose Dose: 900 ug, 2 times / day Route: oral Route: multiple Dose: 900 ug, 2 times / day Sources: |
unhealthy, 18 to 75 years Health Status: unhealthy Age Group: 18 to 75 years Sex: M+F Sources: |
Headache | Disc. AE | 900 ug 2 times / day multiple, oral Studied dose Dose: 900 ug, 2 times / day Route: oral Route: multiple Dose: 900 ug, 2 times / day Sources: |
unhealthy, 18 to 75 years Health Status: unhealthy Age Group: 18 to 75 years Sex: M+F Sources: |
Myalgia | Disc. AE | 900 ug 2 times / day multiple, oral Studied dose Dose: 900 ug, 2 times / day Route: oral Route: multiple Dose: 900 ug, 2 times / day Sources: |
unhealthy, 18 to 75 years Health Status: unhealthy Age Group: 18 to 75 years Sex: M+F Sources: |
Nausea | Disc. AE | 900 ug 2 times / day multiple, oral Studied dose Dose: 900 ug, 2 times / day Route: oral Route: multiple Dose: 900 ug, 2 times / day Sources: |
unhealthy, 18 to 75 years Health Status: unhealthy Age Group: 18 to 75 years Sex: M+F Sources: |
Pain in extremity | Disc. AE | 900 ug 2 times / day multiple, oral Studied dose Dose: 900 ug, 2 times / day Route: oral Route: multiple Dose: 900 ug, 2 times / day Sources: |
unhealthy, 18 to 75 years Health Status: unhealthy Age Group: 18 to 75 years Sex: M+F Sources: |
Headache | 65% | 900 ug 2 times / day multiple, oral Studied dose Dose: 900 ug, 2 times / day Route: oral Route: multiple Dose: 900 ug, 2 times / day Sources: |
unhealthy, 19 to 75 years Health Status: unhealthy Age Group: 19 to 75 years Sex: M+F Sources: |
Diarrhoea | 42% | 900 ug 2 times / day multiple, oral Studied dose Dose: 900 ug, 2 times / day Route: oral Route: multiple Dose: 900 ug, 2 times / day Sources: |
unhealthy, 20 to 75 years Health Status: unhealthy Age Group: 20 to 75 years Sex: M+F Sources: |
Pain in jaw | 26% | 900 ug 2 times / day multiple, oral Studied dose Dose: 900 ug, 2 times / day Route: oral Route: multiple Dose: 900 ug, 2 times / day Sources: |
unhealthy, 21 to 75 years Health Status: unhealthy Age Group: 21 to 75 years Sex: M+F Sources: |
Nausea | 33% | 900 ug 2 times / day multiple, oral Studied dose Dose: 900 ug, 2 times / day Route: oral Route: multiple Dose: 900 ug, 2 times / day Sources: |
unhealthy, 22 to 75 years Health Status: unhealthy Age Group: 22 to 75 years Sex: M+F Sources: |
Myalgia | 16% | 900 ug 2 times / day multiple, oral Studied dose Dose: 900 ug, 2 times / day Route: oral Route: multiple Dose: 900 ug, 2 times / day Sources: |
unhealthy, 23 to 75 years Health Status: unhealthy Age Group: 23 to 75 years Sex: M+F Sources: |
Vomiting | 18% | 900 ug 2 times / day multiple, oral Studied dose Dose: 900 ug, 2 times / day Route: oral Route: multiple Dose: 900 ug, 2 times / day Sources: |
unhealthy, 24 to 75 years Health Status: unhealthy Age Group: 24 to 75 years Sex: M+F Sources: |
Pain in extremity | 17% | 900 ug 2 times / day multiple, oral Studied dose Dose: 900 ug, 2 times / day Route: oral Route: multiple Dose: 900 ug, 2 times / day Sources: |
unhealthy, 25 to 75 years Health Status: unhealthy Age Group: 25 to 75 years Sex: M+F Sources: |
Flushing | 12% | 900 ug 2 times / day multiple, oral Studied dose Dose: 900 ug, 2 times / day Route: oral Route: multiple Dose: 900 ug, 2 times / day Sources: |
unhealthy, 26 to 75 years Health Status: unhealthy Age Group: 26 to 75 years Sex: M+F Sources: |
Arthralgia | 11% | 900 ug 2 times / day multiple, oral Studied dose Dose: 900 ug, 2 times / day Route: oral Route: multiple Dose: 900 ug, 2 times / day Sources: |
unhealthy, 27 to 75 years Health Status: unhealthy Age Group: 27 to 75 years Sex: M+F Sources: |
Anaemia | 8% | 900 ug 2 times / day multiple, oral Studied dose Dose: 900 ug, 2 times / day Route: oral Route: multiple Dose: 900 ug, 2 times / day Sources: |
unhealthy, 28 to 75 years Health Status: unhealthy Age Group: 28 to 75 years Sex: M+F Sources: |
Abdominal pain | 8% | 900 ug 2 times / day multiple, oral Studied dose Dose: 900 ug, 2 times / day Route: oral Route: multiple Dose: 900 ug, 2 times / day Sources: |
unhealthy, 29 to 75 years Health Status: unhealthy Age Group: 29 to 75 years Sex: M+F Sources: |
Decreased appetite | 6% | 900 ug 2 times / day multiple, oral Studied dose Dose: 900 ug, 2 times / day Route: oral Route: multiple Dose: 900 ug, 2 times / day Sources: |
unhealthy, 30 to 75 years Health Status: unhealthy Age Group: 30 to 75 years Sex: M+F Sources: |
Pain | 3% | 900 ug 2 times / day multiple, oral Studied dose Dose: 900 ug, 2 times / day Route: oral Route: multiple Dose: 900 ug, 2 times / day Sources: |
unhealthy, 31 to 75 years Health Status: unhealthy Age Group: 31 to 75 years Sex: M+F Sources: |
Nasopharyngitis | 13% | 900 ug 2 times / day multiple, oral Studied dose Dose: 900 ug, 2 times / day Route: oral Route: multiple Dose: 900 ug, 2 times / day Sources: |
unhealthy, 32 to 75 years Health Status: unhealthy Age Group: 32 to 75 years Sex: M+F Sources: |
Nausea | 12.5% Disc. AE |
1800 ug 2 times / day multiple, oral Highest studied dose Dose: 1800 ug, 2 times / day Route: oral Route: multiple Dose: 1800 ug, 2 times / day Sources: |
healthy, mean age of 36.4 years Health Status: healthy Age Group: mean age of 36.4 years Sex: M Sources: |
Nightmares | 12.5% Disc. AE |
1800 ug 2 times / day multiple, oral Highest studied dose Dose: 1800 ug, 2 times / day Route: oral Route: multiple Dose: 1800 ug, 2 times / day Sources: |
healthy, mean age of 36.4 years Health Status: healthy Age Group: mean age of 36.4 years Sex: M Sources: |
Headache | 11.1% Disc. AE |
1000 ug 2 times / day multiple, oral Studied dose Dose: 1000 ug, 2 times / day Route: oral Route: multiple Dose: 1000 ug, 2 times / day Sources: |
healthy, mean age of 36.4 years Health Status: healthy Age Group: mean age of 36.4 years Sex: M Sources: |
Myalgia | 8.3% Disc. AE |
400 ug 2 times / day multiple, oral Studied dose Dose: 400 ug, 2 times / day Route: oral Route: multiple Dose: 400 ug, 2 times / day Sources: |
healthy, mean age of 36.4 years Health Status: healthy Age Group: mean age of 36.4 years Sex: M Sources: |
Disturbance in attention | 9.1% Disc. AE |
600 ug 2 times / day multiple, oral Studied dose Dose: 600 ug, 2 times / day Route: oral Route: multiple Dose: 600 ug, 2 times / day Sources: |
healthy, mean age of 36.4 years Health Status: healthy Age Group: mean age of 36.4 years Sex: M Sources: |
Dizziness | 9.1% Disc. AE |
600 ug 2 times / day multiple, oral Studied dose Dose: 600 ug, 2 times / day Route: oral Route: multiple Dose: 600 ug, 2 times / day Sources: |
healthy, mean age of 36.4 years Health Status: healthy Age Group: mean age of 36.4 years Sex: M Sources: |
Dry mouth | 9.1% Disc. AE |
600 ug 2 times / day multiple, oral Studied dose Dose: 600 ug, 2 times / day Route: oral Route: multiple Dose: 600 ug, 2 times / day Sources: |
healthy, mean age of 36.4 years Health Status: healthy Age Group: mean age of 36.4 years Sex: M Sources: |
Dysaesthesia | 9.1% Disc. AE |
600 ug 2 times / day multiple, oral Studied dose Dose: 600 ug, 2 times / day Route: oral Route: multiple Dose: 600 ug, 2 times / day Sources: |
healthy, mean age of 36.4 years Health Status: healthy Age Group: mean age of 36.4 years Sex: M Sources: |
Feeling hot | 9.1% Disc. AE |
600 ug 2 times / day multiple, oral Studied dose Dose: 600 ug, 2 times / day Route: oral Route: multiple Dose: 600 ug, 2 times / day Sources: |
healthy, mean age of 36.4 years Health Status: healthy Age Group: mean age of 36.4 years Sex: M Sources: |
Myalgia | 9.1% Disc. AE |
600 ug 2 times / day multiple, oral Studied dose Dose: 600 ug, 2 times / day Route: oral Route: multiple Dose: 600 ug, 2 times / day Sources: |
healthy, mean age of 36.4 years Health Status: healthy Age Group: mean age of 36.4 years Sex: M Sources: |
Palpitations | 9.1% Disc. AE |
600 ug 2 times / day multiple, oral Studied dose Dose: 600 ug, 2 times / day Route: oral Route: multiple Dose: 600 ug, 2 times / day Sources: |
healthy, mean age of 36.4 years Health Status: healthy Age Group: mean age of 36.4 years Sex: M Sources: |
Tinnitus | 9.1% Disc. AE |
600 ug 2 times / day multiple, oral Studied dose Dose: 600 ug, 2 times / day Route: oral Route: multiple Dose: 600 ug, 2 times / day Sources: |
healthy, mean age of 36.4 years Health Status: healthy Age Group: mean age of 36.4 years Sex: M Sources: |
Nausea | 3200 ug 1 times / day single, oral Studied dose Dose: 3200 ug, 1 times / day Route: oral Route: single Dose: 3200 ug, 1 times / day Sources: |
unhealthy |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Drug as perpetrator
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207947Orig1s000ClinPharmR.pdf#page=21 Page: 21.0 |
no | |||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207947Orig1s000ClinPharmR.pdf#page=21 Page: 21.0 |
no | |||
yes | ||||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207947Orig1s000ClinPharmR.pdf#page=21 Page: 21.0 |
yes | |||
Page: 10.0 |
yes | |||
Page: 10.0 |
yes | |||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207947Orig1s000ClinPharmR.pdf#page=21 Page: 21.0 |
yes | |||
Page: 10.0 |
yes | |||
Page: 10.0 |
yes | |||
yes | no (co-administration study) Comment: Co-administration of Kaletra® [CYP3A, P-gp and OATP1B1/1B3 inhibitor] with selexipag resulted in approx. 2-fold increase in the exposure to selexipag, but not ACT-333679. Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207947Orig1s000ClinPharmR.pdf#page=6 Page: 6.0 |
|||
yes | no (co-administration study) Comment: Co-administration of Kaletra® [CYP3A, P-gp and OATP1B1/1B3 inhibitor] with selexipag resulted in approx. 2-fold increase in the exposure to selexipag, but not ACT-333679. Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207947Orig1s000ClinPharmR.pdf#page=6 Page: 6.0 |
|||
yes | no (co-administration study) Comment: Co-administration of Kaletra® [CYP3A, P-gp and OATP1B1/1B3 inhibitor] with selexipag resulted in approx. 2-fold increase in the exposure to selexipag, but not ACT-333679. Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207947Orig1s000ClinPharmR.pdf#page=6 Page: 6.0 |
|||
yes | no (co-administration study) Comment: Co-administration of Kaletra® [CYP3A, P-gp and OATP1B1/1B3 inhibitor] with selexipag resulted in approx. 2-fold increase in the exposure to selexipag, but not ACT-333679. Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207947Orig1s000ClinPharmR.pdf#page=6 Page: 6.0 |
|||
yes | no (co-administration study) Comment: Co-administration of Kaletra® [CYP3A, P-gp and OATP1B1/1B3 inhibitor] with selexipag resulted in approx. 2-fold increase in the exposure to selexipag, but not ACT-333679. Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207947Orig1s000ClinPharmR.pdf#page=6 Page: 6.0 |
Tox targets
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207947Orig1s000PharmR.pdf#page=75 Page: 75.0 |
PubMed
Title | Date | PubMed |
---|---|---|
An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. | 1976 Oct 21 |
|
Prostanoid receptors and their biological actions. | 1993 |
|
Synthesis and evaluation of N-acylsulfonamide and N-acylsulfonylurea prodrugs of a prostacyclin receptor agonist. | 2007 Dec 15 |
|
Structure-activity studies on diphenylpyrazine derivatives: a novel class of prostacyclin receptor agonists. | 2007 Nov 1 |
|
2-[4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy]-N-(methylsulfonyl)acetamide (NS-304), an orally available and long-acting prostacyclin receptor agonist prodrug. | 2007 Sep |
|
Selexipag: a selective prostacyclin receptor agonist that does not affect rat gastric function. | 2010 Oct |
|
Pathways in pulmonary arterial hypertension: the future is here. | 2012 Dec 1 |
|
Pharmacokinetics and Tolerability of the Novel Oral Prostacyclin IP Receptor Agonist Selexipag. | 2015 Jun |
|
Selexipag for the treatment of pulmonary arterial hypertension. | 2016 |
Sample Use Guides
Starting dose: 200 mcg twice daily.
Increase the dose by 200 mcg twice daily at weekly intervals to the highest tolerated dose up to 1600 mcg twice daily.
Maintenance dose is determined by tolerability.
Moderate hepatic impairment: Starting dose 200 mcg once daily, increase the dose by 200 mcg once daily at weekly intervals to the highest tolerated dose up to 1600 mcg.
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Apr 02 09:07:10 GMT 2025
by
admin
on
Wed Apr 02 09:07:10 GMT 2025
|
Record UNII |
5EXC0E384L
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NDF-RT |
N0000192339
Created by
admin on Wed Apr 02 09:07:10 GMT 2025 , Edited by admin on Wed Apr 02 09:07:10 GMT 2025
|
||
|
FDA ORPHAN DRUG |
652018
Created by
admin on Wed Apr 02 09:07:10 GMT 2025 , Edited by admin on Wed Apr 02 09:07:10 GMT 2025
|
||
|
WHO-ATC |
B01AC27
Created by
admin on Wed Apr 02 09:07:10 GMT 2025 , Edited by admin on Wed Apr 02 09:07:10 GMT 2025
|
||
|
NCI_THESAURUS |
C78568
Created by
admin on Wed Apr 02 09:07:10 GMT 2025 , Edited by admin on Wed Apr 02 09:07:10 GMT 2025
|
||
|
EMA ASSESSMENT REPORTS |
UPTRAVI (AUTHORIZED: HYPERTENSION, PULMONARY)
Created by
admin on Wed Apr 02 09:07:10 GMT 2025 , Edited by admin on Wed Apr 02 09:07:10 GMT 2025
|
||
|
FDA ORPHAN DRUG |
304810
Created by
admin on Wed Apr 02 09:07:10 GMT 2025 , Edited by admin on Wed Apr 02 09:07:10 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
1729002
Created by
admin on Wed Apr 02 09:07:10 GMT 2025 , Edited by admin on Wed Apr 02 09:07:10 GMT 2025
|
PRIMARY | |||
|
CHEMBL238804
Created by
admin on Wed Apr 02 09:07:10 GMT 2025 , Edited by admin on Wed Apr 02 09:07:10 GMT 2025
|
PRIMARY | |||
|
Selexipag
Created by
admin on Wed Apr 02 09:07:10 GMT 2025 , Edited by admin on Wed Apr 02 09:07:10 GMT 2025
|
PRIMARY | |||
|
9913767
Created by
admin on Wed Apr 02 09:07:10 GMT 2025 , Edited by admin on Wed Apr 02 09:07:10 GMT 2025
|
PRIMARY | |||
|
5EXC0E384L
Created by
admin on Wed Apr 02 09:07:10 GMT 2025 , Edited by admin on Wed Apr 02 09:07:10 GMT 2025
|
PRIMARY | |||
|
m11914
Created by
admin on Wed Apr 02 09:07:10 GMT 2025 , Edited by admin on Wed Apr 02 09:07:10 GMT 2025
|
PRIMARY | |||
|
C152321
Created by
admin on Wed Apr 02 09:07:10 GMT 2025 , Edited by admin on Wed Apr 02 09:07:10 GMT 2025
|
PRIMARY | |||
|
DB11362
Created by
admin on Wed Apr 02 09:07:10 GMT 2025 , Edited by admin on Wed Apr 02 09:07:10 GMT 2025
|
PRIMARY | |||
|
100000156702
Created by
admin on Wed Apr 02 09:07:10 GMT 2025 , Edited by admin on Wed Apr 02 09:07:10 GMT 2025
|
PRIMARY | |||
|
90844
Created by
admin on Wed Apr 02 09:07:10 GMT 2025 , Edited by admin on Wed Apr 02 09:07:10 GMT 2025
|
PRIMARY | |||
|
5077
Created by
admin on Wed Apr 02 09:07:10 GMT 2025 , Edited by admin on Wed Apr 02 09:07:10 GMT 2025
|
PRIMARY | |||
|
475086-01-2
Created by
admin on Wed Apr 02 09:07:10 GMT 2025 , Edited by admin on Wed Apr 02 09:07:10 GMT 2025
|
PRIMARY | |||
|
9231
Created by
admin on Wed Apr 02 09:07:10 GMT 2025 , Edited by admin on Wed Apr 02 09:07:10 GMT 2025
|
PRIMARY | |||
|
DTXSID301027959
Created by
admin on Wed Apr 02 09:07:10 GMT 2025 , Edited by admin on Wed Apr 02 09:07:10 GMT 2025
|
PRIMARY | |||
|
YY-107
Created by
admin on Wed Apr 02 09:07:10 GMT 2025 , Edited by admin on Wed Apr 02 09:07:10 GMT 2025
|
PRIMARY | |||
|
SUB130805
Created by
admin on Wed Apr 02 09:07:10 GMT 2025 , Edited by admin on Wed Apr 02 09:07:10 GMT 2025
|
PRIMARY | |||
|
EU/3/05/316(WITHDRAWN)
Created by
admin on Wed Apr 02 09:07:10 GMT 2025 , Edited by admin on Wed Apr 02 09:07:10 GMT 2025
|
PRIMARY | Please note that this product was withdrawn from the Community Register of designated Orphan Medicinal Products in February 2016 on request of the Sponsor, at the time of the granting of a marketing authorisation. On 26 August 2005, orphan designation (EU/3/05/316) was granted by the European Commission to Nippon Shinyaku Co. Ltd, Germany, for 2-{4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N-(methylsulfonyl)acetamide for the treatment of pulmonary arterial hypertension and chronic thromoembolic pulmonary hypertension. The sponsorship was transferred to Actelion Registration Limited, United Kingdom, in February 2009. Update: 2-{4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N-(methylsulfonyl)acetamide has been authorised in the EU as Uptravi since 12 May 2016. More information on Uptravi can be found in the European public assessment report (EPAR) on the Agency’s website. | ||
|
N0000020068
Created by
admin on Wed Apr 02 09:07:10 GMT 2025 , Edited by admin on Wed Apr 02 09:07:10 GMT 2025
|
PRIMARY | Prostacyclin Receptor Agonists [MoA] | ||
|
5EXC0E384L
Created by
admin on Wed Apr 02 09:07:10 GMT 2025 , Edited by admin on Wed Apr 02 09:07:10 GMT 2025
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
TRANSPORTER -> INHIBITOR |
IC50
|
||
|
TRANSPORTER -> SUBSTRATE | |||
|
TRANSPORTER -> SUBSTRATE | |||
|
TRANSPORTER -> SUBSTRATE | |||
|
TRANSPORTER -> INHIBITOR |
IC50
|
||
|
BINDER->LIGAND |
BINDING
|
||
|
TRANSPORTER -> INHIBITOR |
IC50
|
||
|
METABOLIC ENZYME -> INHIBITOR |
IC50
|
||
|
EXCRETED UNCHANGED |
No unchanged selexipag is excreted in the urine and feces.
FECAL; URINE
|
||
|
TRANSPORTER -> INHIBITOR |
IC50
|
||
|
METABOLIC ENZYME -> SUBSTRATE |
MAJOR
|
||
|
METABOLIC ENZYME -> INHIBITOR |
IC50
|
||
|
TARGET -> AGONIST |
EC50
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE ACTIVE -> PARENT |
|
||
|
METABOLITE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Biological Half-life | PHARMACOKINETIC |
|
|
|||
Volume of Distribution | PHARMACOKINETIC |
|
|
|||
Tmax | PHARMACOKINETIC |
|
ORAL ADMINISTRATION |
|
||